Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could your own belly fat help fight MS?

NCT ID NCT03461419

Disease control Sponsor: Healeon Medical Inc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether a patient's own fat cells, processed into a special mixture called stromal vascular fraction, can safely improve quality of life and slow nerve damage in multiple sclerosis. About 100 adults with stable MS who have lasting nerve problems will receive an IV infusion of their own cells. The trial is currently suspended, and it is too early to know if this approach works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
autologous adipose-derived cellular stromal vascular fraction (AD-cSVF)
What this could lead to
If it works, this could point toward a new way to manage multiple sclerosis by using the body's own cells to calm the immune system.
What could go wrong
The trial is suspended and early-stage, with no phase assigned. It is small (100 people) and uses a complex procedure that may not show clear benefit or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2019

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Documented functional damage to central or peripheral nervous system unlikely to improve with present standard of care * At least 6 months after onset of disease process * If under current medical therapy (drug or surgical) for the condition, patient considered stable on that treatment and unlikely to have significant reversal of associated neurological functions damage as a result of ongoing treatments * In estimation of providers and neurologists have the potential for improvement with AD-cSVF treatment, and be at minimal risk of potential harm from the procedure * Over 18 year old, and capable of providing informed consent * Medically stable and cleared by primary care physician, neurologist, or licensed practitioner that patient is felt to be reasonably expected to be expected to undergo procedures without known significant risk to health Exclusion Criteria: * Patient must be capable of an adequate neurologic examination and evaluation to document the pathology and ability to cooperate with examination * Patient must be capable and willing to undergo follow up neurologic exams with investigators or their own neurologists * Patient must be capable and competent to provide informed consent to participation * In estimation of investigators, the patient may be at increased or significant risk of harm to the patient's general health or neurologic functions for collection of AD-cSVF collection * Patients not medically stable, or who may be at significant risk to their health undergoing any and all procedures will not be eligible * Women of childbearing age must not be pregnant at the time of treatment, and should refrain from becoming pregnant for 3 months post-treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autoimmune are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune disease demyelinating disease multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autoimmune Multiple sclerosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Global Alliance of Regenerative Medicine (GARM) International

    Roatán, Hn, Honduras, Honduras

  • Robert W. Alexander, MD, FICS, LLC

    Stevensville, Montana, 59870, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.